Milliman
Oncology Drug Spending Set to Double by 2030, Spanning Medicare, Medicaid, and Commercial Markets
Milliman projects U.S. oncology drug spending will grow from roughly $200 billion in 2025 to over $400 billion by 2030, driven by pipeline launches, expanded indications, and the unique dynamic of oncology drugs spanning both medical and pharmacy benefits. The paper discusses how Medicare's Inflation Reduction Act drug price negotiation program and evolving generic/biosimilar competition will reshape costs across Medicare, commercial, and Medicaid markets, which matters for Medicaid pharmacy benefit managers and MCOs managing specialty drug spend, though Medicaid-specific dynamics are not the primary focus.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.